Changing Breast Cancer Treatment with the NeoNavia[®] Biopsy System
Following recent FDA clearance of NeoNavia, NeoDynamics announces US launch with its accompanying FlexiPulse™probeStockholm, Sweden, October 25, 2022 NeoDynamics AB (Nasdaq First North Growth Market Stockholm: NEOD.ST), a medical device company dedicated to advancing the diagnosis and care of cancer, announced today that it is launching the NeoNavia biopsy system configured with its FlexiPulse probe in the United States to support the diagnosis of cancer. “The recent FDA clearance of the NeoNavia will help clinicians address the critical issues they face in diagnosing and treating breast